Alan Weichselbaum - 15 May 2025 Form 3 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)

Role: Chief Financial Officer
Signature: /s/ Alan Weichselbaum
Issuer symbol: TELO
Transactions as of: 15 May 2025
Net transactions value: $0
Form type: 3
Filing time: 10 Jun 2025, 07:12:56 UTC
Previous filing: 29 May 2024
Next filing: 29 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Weichselbaum Alan	Chief Financial Officer	C/O TELOMIR PHARMACEUTICALS, INC., 100 SE 2ND ST, SUITE 2000, #1009, MIAMI	/s/ Alan Weichselbaum	10 Jun 2025	0001435390

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TELO	Stock Options (right to buy)							15 May 2025	Common Stock	50,000	$2.75	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (25,000) of the options will vest six (6) months following May 14, 2025, and twenty-five thousand (25,000) of the option will vest twelve (12) months following May 13, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date.

Content

The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (25,000) of the options will vest six (6) months following May 14, 2025, and twenty-five thousand (25,000) of the option will vest twelve (12) months following May 13, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date.